C4 Therapeutics, Inc. (CCCC) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for C4 Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -1.51x | -2.37x | -2.12x | -2.25x | -17.67x | -21.51x |
| P/B Ratio | 0.62x | 1.16x | 1.14x | 1.00x | 3.81x | 5.08x |
| P/S Ratio | 4.40x | 7.02x | 13.51x | 9.27x | 32.38x | 42.98x |
| Profitability | ||||||
| Gross Margin | 77.8% | 100.0% | 62.7% | 100.0% | 100.0% | -136.3% |
| Operating Margin | -290.7% | -336.1% | -669.8% | -416.6% | -179.4% | -182.1% |
| Net Margin | -292.1% | -296.0% | -638.3% | -412.2% | -183.2% | -199.8% |
| EBITDA Margin | -286.3% | -290.5% | -588.3% | -399.7% | -175.3% | -177.2% |
| Liquidity | ||||||
| Current Ratio | 7.81x | 5.71x | 6.34x | 6.46x | 6.36x | 8.69x |
| Quick Ratio | 7.81x | 5.71x | 6.34x | 7.82x | 6.36x | 8.69x |
| Leverage | ||||||
| Debt/Equity | 0.23x | 0.30x | 0.29x | 0.30x | 0.11x | 0.08x |
YoY = year-over-year change. Source: FMP..